News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astellas (ALPMY) Extends Commitment With The Canadian Urological Association To Advance Research In Canada



11/18/2016 8:57:33 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Research applications now being accepted for the 2017 competition

MARKHAM, ON, Nov. 18, 2016 /CNW/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. (Astellas) are pleased to announce the renewal of the CUA Astellas Research Grant Program for an additional three years.

The research grant program was originally launched in 2012, initiating a five year commitment to support scientific discovery and innovation within the urologic scientific community.  With this renewed commitment, Astellas pledges an additional $450,000 over three years to continue to support Canadian peer-reviewed research in urology, with the ultimate goal of improving patient care.

The primary focus of the program is to support research in the area of functional urology such as over active bladder (OAB), lower urinary tract symptoms (LUTS), pelvic floor disorders, voiding dysfunctions, and neurogenic bladder. Secondary areas of focus could include other urological areas such as community-based research, practice improvement, multidisciplinary management, basic research, etc. Grant recipients are expected to demonstrate improved understanding of their specific research area and/or contribute to improving patient care.

"The Canadian Urological Association Scholarship Foundation (CUASF) is very thankful and relies on the continued support from Astellas to provide critical funding for our members of the CUA involved in research in areas of functional urology," said Dr. Jonathan Izawa, chair of the CUASF scientific council.

"We are proud to continue our support of the CUA Astellas Research Grant Program and through it, promising advances in urology research that can result in better outcomes for patients," said Fran Paradiso-Hardy, Senior Director, Medical Affairs at Astellas Pharma Canada.

Proposals for the 2017 CUA Astellas Research Grant Program are now being accepted. The submission deadline is February 28th, 2017.  Additional details regarding the eligibility criteria and application process can be found on both the CUA and Astellas websites:

www.cua.org
www.astellas.ca

About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.

The goals of the CUA are to:

  • To foster and promote excellence in urologic practice through education and research.
  • To provide leadership in promoting evidence based clinical practice through the development of practice guidelines.
  • To foster and promote life-long learning by Canadian urologists through continuous professional development.
  • To provide leadership in public education for urologic diseases.
  • To represent Canadian urology in developing and fostering partnerships while maintaining the highest educational and ethical standards.
  • To represent the Canadian urologic community in relationships with national and international medical societies.

More information about CUA can be found at www.cua.org

About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.  For more information, please visit our website at www.astellas.com/en

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on four therapeutic areas Urology, Immunology, Infectious Disease, and Oncology. For more information about Astellas Pharma Canada, Inc., please visit the corporate website:  www.astellas.ca

SOURCE Astellas Pharma Canada, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES